文献速递脑血管病神经重症与神经感染

脑出血患者血压下降的最佳幅度与血肿增长及功能结局

Optimal Magnitude of Blood Pressure Reduction and Hematoma Growth and Functional Outcomes in Intracerebral Hemorrhage.
PubMed 文献 · Neurology · 2025-02-06

本研究为ATACH-2试验的事后分析,纳入925例基线收缩压≥180 mmHg的脑出血患者,按2小时内收缩压下降幅度分为5组。结果显示收缩压下降≥70 mmHg与血肿扩大风险降低相关,下降≥55 mmHg与不良功能结局风险降低相关(OR 0.49,95% CI 0.28-0.85),但下降≥85 mmHg增加急性肾损伤风险(OR 2.00,95% CI 1.01-3.94)。作者认为2小时内收缩压下降55-85 mmHg可能与最佳结局相关。

要点

  • 2小时内收缩压下降≥70 mmHg与血肿扩大风险降低相关。
  • 收缩压下降≥55 mmHg与不良功能结局风险降低相关(OR 0.49)。
  • 收缩压下降≥85 mmHg较<40 mmHg增加急性肾损伤风险(OR 2.00)。

核心结论

  • 对于轻至中度脑出血患者,2小时内收缩压下降55-85 mmHg似乎与最佳结局相关,可平衡限制血肿增长与避免不良反应的需要。
  • 作者认为需进一步开展针对严重脑出血的研究。

研究设计与样本

  • ATACH-2试验的事后分析,纳入基线收缩压≥180 mmHg且在发病4.5小时内随机化的患者,分为强化组或标准组。
  • 共纳入925例患者,其中360例(38.9%)为女性,中位年龄62岁(IQR 53-71)。
  • 按2小时内收缩压下降幅度(入院收缩压减2小时最低收缩压)以15 mmHg分层分为5组:<40、40-55、55-70、70-85和≥85 mmHg。

主要发现

  • 中位血肿体积为10.2 mL(IQR 5.1-18.4),中位收缩压下降幅度为68 mmHg(IQR 48-88)。
  • 209例(22.6%)发生血肿扩大,122例(13.2%)发生急性肾损伤,516例(55.8%)不良结局。
  • 随着血压下降幅度增加,5个收缩压下降组血肿扩大呈线性减少(p < 0.001)。
  • 多因素校正后,收缩压下降≥70 mmHg的患者发生血肿扩大的可能性更低;收缩压下降≥55 mmHg与不良结局风险降低相关(OR 0.49,95% CI 0.28-0.85)。
  • 与<40 mmHg相比,收缩压下降≥85 mmHg增加急性肾损伤风险(OR 2.00,95% CI 1.01-3.94)。

关键数值与推荐

  • 不良功能结局定义为3-6个月时改良Rankin量表评分。
  • 血肿扩大定义为从基线至24小时相对增加>33%。
  • 收缩压下降≥55 mmHg与不良结局风险降低相关(OR 0.49,95% CI 0.28-0.85)。
  • 收缩压下降≥85 mmHg较<40 mmHg增加急性肾损伤风险(OR 2.00,95% CI 1.01-3.94)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为事后分析,证据等级为Class III。
  • 作者认为需进一步开展针对严重脑出血的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Early intensive systolic blood pressure (SBP) reduction is a promising strategy for intracerebral hemorrhage (ICH), but the optimal magnitude of reduction in the first 2 hours remains uncertain. This study aimed to determine the optimal SBP reduction magnitude to maximize benefit in patients enrolled in the Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) trial. METHODS: We performed a post hoc analysis of the ATACH-2 trial. Participants with baseline SBP ≥180 mm Hg were randomized within 4.5 hours from onset and assigned to the intensive or standard group. The magnitude of SBP reduction was calculated as admission SBP minus minimum SBP at 2 hours. Eligible participants were divided into 5 groups by 15 mm Hg stratum: <40, 40-55, 55-70, 70-85, and ≥85 mm Hg. Poor functional outcome was defined as the modified Rankin Scale score at 3-6 and hematoma expansion (HE) as a relative increase of >33% from baseline to 24 hours. Multivariable logistic regression assessed associations between SBP reduction and outcomes. RESULTS: Our study included 925 patients, of whom 360 (38.9%) were female. The median age was 62 years (IQR: 53-71). The median hematoma volume was 10.2 mL (IQR: 5.1-18.4), and the median magnitude of SBP reduction was 68 mm Hg (IQR: 48-88). Of those, 209 (22.6%) experienced HE, 122 (13.2%) experienced acute kidney injury (AKI), and 516 (55.8%) had poor outcome. Hematoma expansion decreased linearly as the magnitude of blood pressure reduction increased in 5 SBP reduction groups (p < 0.001). After multivariable adjustment, patients with a greater degree of SBP reduction (≥70 mm Hg) were less likely to experience HE and a SBP reduction ≥55 mm Hg was associated with a lower risk of poor outcomes (odds ratio [OR] 0.49, 95% CI 0.28-0.85). However, a SBP reduction ≥85 mm Hg increased AKI risk compared with <40 mm Hg (OR, 2.00; 95% CI 1.01-3.94). DISCUSSION: Targeting a SBP reduction within the range of 55-85 mm Hg during the first 2 hours seems to be associated with optimal outcomes in patients with mild-to-moderate ICH, balancing the need to limit hematoma growth while avoiding adverse effect. Further study focusing on severe ICH is warranted. TRIAL REGISTRATION INFORMATION: Clinical trial registration number: NCT01176565. CLASSIFICATION OF EVIDENCE: This post hoc analysis of the ATACH-2 trial provides Class III evidence that SBP reduction of 55-85 mm Hg during the initial 2 hours is associated with lower frequency of HE and better functional outcomes in patients with acute cerebral hemorrhage.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Li Q, Lv X, Morotti A, et al. Optimal Magnitude of Blood Pressure Reduction and Hematoma Growth and Functional Outcomes in Intracerebral Hemorrhage. Neurology. 2025. PMID: 39913881. doi:10.1212/WNL.0000000000213412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。